

HEXIMA LIMITED

ASX ANNOUNCEMENT



26 October 2021

HEXIMA PRESENTING AT AUSBIOTECH

MELBOURNE, AUSTRALIA (26 October 2021): Hexima Limited (ASX:HXL) attaches its corporate presentation for the AusBiotech “Australia Biotech Invest & Partnering Conference 2021”. The conference is a preeminent opportunity for companies to present their technology and story to a network of potential international partners and investors. Mr Michael Aldridge, CEO of Hexima, will present today at 2:05PM (AEST). Following the presentation, Mr Aldridge will also take part in a Q&A forum with representatives from other life sciences companies.

For more information on the AusBiotech “Australia Biotech Invest & Partnering Conference 2021” or to register your attendance visit the following link:

<https://www.ausbiotechinvestment.com.au/registration>

This announcement is authorised for release to ASX by Michael Aldridge, Managing Director & CEO

Enquiries:

Dr Nicole van der Weerden
Chief Operating Officer
n.vanderweerden@hexima.com.au

To join our email database and receive company announcements please [click here](#)

ABOUT HEXIMA

Hexima (ASX:HXL) is a clinical stage, anti-infectives focused biotechnology company engaged in the research and development of defensin peptides for applications as human therapeutics. Our lead product candidate, pezadeftide (HXP124) applied in a topical formulation, is a potential new prescription treatment for toenail fungal infections (or onychomycosis). Hexima is currently conducting an Australian phase IIb clinical trial testing pezadeftide for the treatment of onychomycosis. Hexima holds granted, long-life patents protecting pezadeftide in major markets globally. For additional information please visit www.hexima.com.au. You can also find us on [Twitter](#) and [LinkedIn](#) or email us at info@hexima.com.au.

OCTOBER 2021

HEXIMA LIMITED (ASX:HXL)

A game-changing treatment for onychomycosis



DISCLAIMER

Summary information

This presentation has been prepared by Hexima Ltd and its subsidiaries (collectively “**Hexima**”). The information in this presentation is of general background in summary form which is current as of September 2021 and does not purport to be complete. It does not contain all information relevant or necessary for an investment decision or that would be required to be included in a prospectus under the Corporations Act 2001 (Cth) (**Corporations Act**). The information in this presentation is subject to change without notice. No representation or warranty, express or implied, is made by Hexima or any of its advisers as to the accuracy, adequacy or reliability of any information contained in this presentation.

Not an offer

This presentation is not a prospectus or any other offering document under Australian law or any other law (and will not be lodged with ASIC). This presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. The distribution of this presentation outside Australia may be restricted by law. Any recipient of this presentation who is outside Australia must seek advice on and observe any such restrictions. This presentation may not be reproduced or published, in whole or in part, for any purpose without the prior written permission of Hexima. An investment in securities is subject to known and unknown risks, some of which are beyond the control of Hexima, including possible loss of income and principal invested. Hexima does not guarantee any particular rate of return or the performance of Hexima, nor does it guarantee any particular tax treatment. Investors should have regard to potential risks outlined in this presentation when making their investment decision.

Not financial or product advice

This presentation is for information purposes only and is not a prospectus, product disclosure statement or other offer document under Australian law or the law of any other jurisdiction. This document is not a financial product or investment advice, or a recommendation to acquire securities in Hexima, nor is it legal or tax advice. It has been prepared without taking into account the objectives, financial situation or needs of individuals. You are solely responsible for seeking independent and professional advice in relation to the information contained in this presentation and any action taken on the basis of that information. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial and tax situation and needs and seek legal and taxation advice appropriate to their jurisdiction. No reliance may be placed for any purpose whatsoever on the information included in this presentation or on its accuracy or completeness.

Financial data

All dollar values are in Australian dollars (A\$) unless stated otherwise.

Performance

Past performance information given in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of future performance. The presentation includes forward-looking statements regarding future

events and the future financial performance of Hexima. Forward looking words such as “expect”, “should”, “could”, “may”, “predict”, “plan”, “will”, “believe”, “forecast”, “estimate”, “target” or other similar expressions are intended to identify forward-looking statements. Any forward looking statements included in this document involve subjective judgment and analysis and are subject to significant uncertainties, risks and contingencies, many of which are outside the control of, and are unknown to, Hexima and its officers, employees, agents or associates. In particular, factors such as outcomes of clinical trials and regulatory decisions and processes may affect the future operating and financial performance of Hexima. This may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. The information also assumes the success of Hexima’s business strategies. The success of the strategies is subject to uncertainties and contingencies beyond control, and no assurance can be given that the anticipated benefits from the strategies will be realised in the periods for which forecasts have been prepared or otherwise. Given these uncertainties, you are cautioned to not place undue reliance on any such forward looking statements. Hexima is providing this information as of the date of this presentation and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

Disclaimer

Except as required by law, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness, reliability or correctness of the Information, opinions and conclusions, or as to the reasonableness of any assumption contained in this presentation. By receiving this presentation and to the extent permitted by law, you release Hexima and its officers, employees, agents and associates from any liability (including, without limitation, in respect of direct, indirect or consequential loss or damage or loss or damage arising by negligence) arising as a result of the reliance by you or any other person on anything contained in or omitted from this presentation. To the maximum extent permitted by law, Hexima and its respective advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents exclude and disclaim all liability, including without limitation for negligence or for any expenses, losses, damages or costs incurred by you as a result of the information in the presentation being inaccurate or incomplete in any way for any reason, whether by negligence or otherwise. To the maximum extent permitted by law, Hexima and its advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of information in this presentation.

NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES



HEXIMA LIMITED (ASX:HXL)

DEVELOPING A NOVEL TOPICAL PRODUCT ADDRESSING A CLEAR UNMET NEED IN A LARGE AND GROWING MARKET



**CLINICAL-STAGE,
INFECTIOUS DISEASE-FOCUSED
BIOTECHNOLOGY COMPANY**



**LARGE AND GROWING
MARKET WITH SUBSTANTIAL
UNMET NEED**



**NOVEL, PROPRIETARY
MOLECULE WITH
UNIQUE MOA**



**PEZADEFTIDE ADDRESSES
AN UNMET NEED. GOAL TO BE
THE TREATMENT OF CHOICE**



**WELL-DEFINED
DEVELOPMENT PATH**

Lead program is pezadeftide (HXP124), a **potential new topical treatment** for onychomycosis (fungal nail infections)

Exploring other applications for its anti-fungal peptide platform

Onychomycosis **affects ~14% of the US population**. Global market for treatments for onychomycosis **US\$3.7 bn**

Current treatments do not meet patient needs

- Topical drugs - long course of treatment, limited efficacy
- Oral drugs - more effective but risk of toxic side effects

Patients and clinicians have a **clear preference for a safe topical product** with a more convenient **shorter course of therapy and better efficacy**

Pezadeftide is a patented biologic with a **novel fungicidal mode of action**

Rapidly penetrates the human nail to target the site of infection

Demonstrated in a phase I/IIa clinical trial to have a favourable safety profile and deliver effective and rapid anti-fungal treatment

Safe and well tolerated

High efficacy via consumer-friendly topical application

Short, convenient course of therapy, delivers rapid resolution of disease

Currently in Australian phase IIb clinical trial – results Q2 2022
File IND with FDA in Q4 2021
Phase III 2022



PEZADEFTIDE IN ACTION

Click to play
animation



EXISTING THERAPIES DO NOT MEET CONSUMER NEEDS

CLEAR MARKET NEED FOR A SAFE, CONVENIENT AND MORE EFFECTIVE TOPICAL PRODUCT

TOPICAL TREATMENTS



Long treatments,
poor efficacy

ORAL DRUGS



Better efficacy but potential
for serious adverse events



Patients with
onychomycosis
reluctant to use **oral
drugs** because of
potential toxicity



Topical products
are therefore
strongly preferred



However, **existing
topicals** suffer from
low efficacy rates and
long courses
of therapy



Patients often **stop
treatment** because
the appearance of
the nail does not
improve for many
months



OUR SOLUTION: PEZADEFTIDE IS A NATURALLY OCCURRING PEPTIDE

ITS UNIQUE PROPERTIES ENABLE RAPID
NAIL PENETRATION AND FUNGAL KILLING

Pezadeftide is a potent broad-spectrum antifungal peptide that has evolved to kill fungal pathogens

- Hydrophilic & highly soluble – drives nail penetration
- Resistant to proteases & extremely stable
- Regulated as a biologic
- Excellent safety profile
- Does not pass through human skin

PEZADEFTIDE MOLECULE



SUCCESSFUL PHASE I/IIA CLINICAL TRIAL

HXP124-ONY-001 – TRIAL DESIGN

Randomised, double blind, vehicle-controlled, ascending dose cohort study


Patients treated nails daily with pezadeftide (or vehicle) for 6 weeks with follow-up at 12 weeks

- 36 patients treated with pezadeftide, 12 treated with vehicle

Cohort 1, 2, 3 escalation cohorts

Cohort 4 expansion cohort

- 30 patients, pezadeftide 2% vs vehicle, 6 weeks dosing



PRIMARY ENDPOINT SAFETY AND TOLERABILITY

HXP124-ONY-001 – NO SYSTEMIC ABSORPTION
AND NO LOCAL REDNESS OR IRRITATION

Pezadeftide is safe and well tolerated

NO DRUG-RELATED ADVERSE EVENTS

Pezadeftide is safe and well tolerated when applied daily for 6 weeks.

NO SYSTEMIC TOXICITY

Pezadeftide accumulated in nails and was still detectable 6 weeks after dosing but was not detected in the bloodstream.




EFFECTIVE AND RAPID ANTI-FUNGAL ACTIVITY

HXP124-ONY-001 – MYCOLOGICAL CURE RATE FOR COHORT 4
30 PATIENTS TREATED AT HIGH DOSE (2%) FOR 6 WEEKS

**Mycological cure* was achieved in 69%
of pezadeftide-treated nails in Cohort 4 within
12 weeks (vehicle 29%)**

- **Mycological Cure* rate at 12 weeks, >2-fold**
higher than current treatments, after only
6 weeks of daily treatment



*Mycological cure: KOH stain negative and culture negative




PEZADEFTIDE RAPIDLY CLEARED THE AFFECTED NAIL AREA

HXP124-ONY-001 – CLEAR NAIL GROWTH FOR COHORT 4
30 PATIENTS TREATED AT HIGH DOSE (2%) FOR 6 WEEKS

Pezadeftide cleared the affected nail area more effectively than vehicle (formulation not containing pezadeftide)

- **Clinical Efficacy*** was achieved in **14%** of **2% pezadeftide-treated nails** within just 12 weeks
- No vehicle-treated nails achieved Clinical Efficacy



*Clinical Efficacy = <10% of the nail area affected.



RAPID AND DRAMATIC IMPROVEMENT IN APPEARANCE OF NAILS

NOTICEABLE IMPROVEMENT IN JUST 2 WEEKS,
ALMOST CLEAR IN 12 WEEKS

Pezadeftide penetrates the nail to kill the fungus, allowing healthy, uninfected nail to grow out

- Clear nail growth continues after dosing has finished

[Click to play animation](#)




PATENT FILED ON COMPLIANCEPAK ASSOCIATED MOBILE APPLICATION



CompliancePak

- No spill / difficult to misplace
- Easy to open / child resistant
- Reinforces FDA use directions
- Connects by QR code to mobile app



Mobile app

- Reinforces FDA use directions (with video)
- Compliance reminders / confirmation of treatment
- Visual tracking of treatment progress
- Teledoc: diagnosis, prescription and refills



POTENTIAL TO DELIVER THE PREFERRED SOLUTION IN A CONSUMER-DRIVEN MARKET

Safe, topical medication



Convenient, short course of therapy



Effective, best-in-class mycological cure



FOR PATIENTS WHO WANT

- An easy-to-apply topical solution
- Rapid improvement in the appearance of the nail
- Early affirmation the drug is working
- A short course of effective treatment

FOR PHYSICIANS WHO WANT

- An effective product that will cure the infection
- A safe product
- To quickly know a patient is responding to therapy


FOR PAYERS WHO WANT

- An effective product that patients will not abandon
- A competitively-priced product



AUSTRALIAN PHASE IIB CLINICAL TRIAL

HXP124-ONY-002



NOTE: DAILY DOSING PERIODS INCLUDE 1-WEEK WASHOUTS EVERY 6 WEEKS

Enrolment
completed
July 2021

- Multi-center, randomised, double blind, vehicle-controlled study
- Primary endpoint safety and tolerability, secondary endpoints Mycological Cure and Clinical Efficacy
- Three active (2% pezadeftide) versus vehicle arms to test optimal dosing strategy
- Safety & efficacy assessed at 13, 24, 36 and 40 weeks, data expected Q2 2022



PEZADEFTIDE: A POTENTIAL SOLUTION FOR A LARGE AND POORLY SERVED MARKET



POORLY SERVED MARKET

Affects 14% of the population
Strong consumer preference for topical products
Clear unmet medical need



NEW AND UNIQUE

Novel molecule with unique mode of action
Strong patent protection and long patent life



SAFE

No systemic effects
No local redness or irritation



CONVENIENT

Easy to apply
Short treatment duration
Rapid clearing of infected nail



EFFECTIVE

Efficiently penetrates the nail
Rapidly kills fungus
Best-in-class mycological cure



CONTACTS

MICHAEL
ALDRIDGE

CHIEF EXECUTIVE OFFICER

m.aldridge@hexima.com.au
+1 650 452 4684

DR NICOLE
VAN DER WEERDEN

CHIEF OPERATING OFFICER

n.vanderweerden@hexima.com.au
+61 407 039 983

hexima.com.au

